HK1245778A1 - 用於治療原發性癌症和癌症擴散的小分子 - Google Patents

用於治療原發性癌症和癌症擴散的小分子

Info

Publication number
HK1245778A1
HK1245778A1 HK18105200.5A HK18105200A HK1245778A1 HK 1245778 A1 HK1245778 A1 HK 1245778A1 HK 18105200 A HK18105200 A HK 18105200A HK 1245778 A1 HK1245778 A1 HK 1245778A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
small molecules
primary
metastasis
Prior art date
Application number
HK18105200.5A
Other languages
English (en)
Inventor
Jean X Jiang
Original Assignee
Jean X Jiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jean X Jiang filed Critical Jean X Jiang
Publication of HK1245778A1 publication Critical patent/HK1245778A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18105200.5A 2015-01-17 2018-04-20 用於治療原發性癌症和癌症擴散的小分子 HK1245778A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562104705P 2015-01-17 2015-01-17
PCT/US2016/013645 WO2016115487A1 (en) 2015-01-17 2016-01-15 Small molecules for the treatment of primary cancer and cancer metastasis

Publications (1)

Publication Number Publication Date
HK1245778A1 true HK1245778A1 (zh) 2018-08-31

Family

ID=56406469

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105200.5A HK1245778A1 (zh) 2015-01-17 2018-04-20 用於治療原發性癌症和癌症擴散的小分子

Country Status (6)

Country Link
US (4) US10214529B2 (zh)
EP (1) EP3245204A4 (zh)
CN (1) CN107428753B (zh)
CA (2) CA2977044C (zh)
HK (1) HK1245778A1 (zh)
WO (1) WO2016115487A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214529B2 (en) * 2015-01-17 2019-02-26 The Board Of Regents Of The University Of Texas System Small molecules for the treatment of primary cancer and cancer metastasis
WO2019079691A1 (en) * 2017-10-19 2019-04-25 Jean Jiang SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
CN109675037B (zh) * 2019-01-25 2021-09-14 南方医科大学 Atp及其受体在制备治疗自闭症药物中的应用
CN114524815B (zh) * 2022-02-23 2023-05-23 华南理工大学 一种8-烷氧基嘌呤衍生物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2005105803A2 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
JP4953456B2 (ja) * 2004-09-30 2012-06-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）として有用な新規なベンゾイミダゾール誘導体
WO2009088518A1 (en) 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
EP2758397A1 (en) 2011-09-20 2014-07-30 F.Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
WO2014074529A1 (en) 2012-11-06 2014-05-15 The Board Of Regents Of The University Of Texas System Methods for treatment of primary cancer and cancer metastasis
US10214529B2 (en) * 2015-01-17 2019-02-26 The Board Of Regents Of The University Of Texas System Small molecules for the treatment of primary cancer and cancer metastasis

Also Published As

Publication number Publication date
WO2016115487A1 (en) 2016-07-21
CA2977044A1 (en) 2016-07-21
US20210206769A1 (en) 2021-07-08
EP3245204A1 (en) 2017-11-22
US11680067B2 (en) 2023-06-20
US10214529B2 (en) 2019-02-26
EP3245204A4 (en) 2018-10-03
CN107428753B (zh) 2020-03-03
US20190169190A1 (en) 2019-06-06
US20180009809A1 (en) 2018-01-11
CA3197570A1 (en) 2016-07-21
CA2977044C (en) 2023-06-27
US20230322782A1 (en) 2023-10-12
CN107428753A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
HK1258098A1 (zh) 治療癌症的方法
HK1251408A1 (zh) 治療癌症的方法
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL261959B1 (en) Cancer treatment with tg02
RS61536B1 (sr) Kombinacije fgfr- i cmet-inhibitora za lečenje kancera
IL259996A (en) Combinations for cancer treatment
IL277261A (en) Low molecular weight compounds for cancer treatment
PL3622953T3 (pl) Leczenie skojarzone nowotworu
IL262342A (en) Cancer treatment methods
EP3157336A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
HK1251927A1 (zh) 用於治療癌症的新穎生物標記和方法
IL263835A (en) Exosome-guided treatment of cancer
HK1245778A1 (zh) 用於治療原發性癌症和癌症擴散的小分子
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer